Nrf2 is a potential therapeutic target in radioresistance in human cancer

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 706-715

  Zhou, Suna ^a   Ye, Wenguang ^a   Shao, Qiuju ^a   Zhang, Mingxin ^a   Liang, Jun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidant; Nrf2; Radioresistance; ROS; Targeted therapy

Indexed keywords

HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; PEROXIREDOXIN; PROTEIN MDM2; RADIOPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2;

BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CANCER STEM CELL; COLORECTAL CANCER; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; GALLBLADDER CANCER; HUMAN; KILLER CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PROSTATE CANCER; RADIOSENSITIVITY; RECEPTOR UPREGULATION; REVIEW;

ANTIOXIDANT; NRF2; RADIORESISTANCE; ROS; TARGETED THERAPY;

ANIMALS; ANTIOXIDANTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84888300793     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.09.001     Document Type: Review

References (138)

1. Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002, 3:420-425.
2. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110.
3. Zhang B., Wang Y., Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009, 286:154-160.
4. Lawenda B.D., Kelly K.M., Ladas E.J., Sagar S.M., Vickers A., Blumberg J.B. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy. J Natl Cancer Inst 2008, 100:773-783.
5. Okunieff P., Swarts S., Keng P., et al. Antioxidants reduce consequences of radiation exposure. Adv Exp Med Biol 2008, 16:5-7. 8.
6. Gudkov A.V., Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003, 3:117-129.
7. Lee H.C., Kim D.W., Jung K.Y., et al. Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. Int J Mol Med 2004, 13:883-887.
8. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
9. Zhang P., Singh A., Yegnasubramanian S., et al. Loss of Keap1 function in prostate cancer cells causes chemo-and radio-resistance and promotes tumor growth. Mol Cancer Ther 2010, 9:336-346.
10. Lee S., Lim M.J., Kim M.H., et al. An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012, 53:807-816.
11. Huang H.C., Nguyen T., Pickett C.B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 2002, 277:42769-42774.
12. Li L., Story M., Legerski R.J. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys 2001, 49:1157-1162.
13. Riley P. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994, 65:27-33.
14. Goodhead D. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994, 65:7-17.
15. Milas L., Hittelman W.N. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 2009, 19:96-105.
16. Pajonk F., Vlashi E., McBride W.H. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010, 28:639-648.
17. Powell S., McMillan T.J. DNA damage and repair following treatment with ionizing radiation. Radiother Oncol 1990, 19:95-108.
18. Borek C. Antioxidants and radiation therapy. J Nutr 2004, 134. 3207S-9S.
19. Park S.H., Chung Y.M., Lee Y.S., et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 2000, 6:4915-4920.
20. Husbeck B., Peehl D.M., Knox S.J. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 2005, 38:50-57.
21. Wang T., Tamae D., LeBon T., Shively J.E., Yen Y., Li J.J. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 2005, 65:10338-10346.
22. Moss R.W. Do antioxidants interfere with radiation therapy for cancer. Integr Cancer Ther 2007, 6:281-292.
23. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
24. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
25. Prince M., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 973-978.
26. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104:10158-10163.
27. Chan K.S., Espinosa I., Chao M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009, 106:14016-14021.
28. Moncharmont C., Levy A., Gilormini M., et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett 2012, 322:139-147.
29. Itoh K., Chiba T., Takahashi S., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313-322.
30. Shibata T., Ohta T., Tong K.I., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008, 105:13568-13573.
31. Kobayashi A., Kang M.I., Okawa H., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24:7130-7139.
32. Kobayashi M., Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 2006, 46:113-140.
33. Meyer U.A. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996, 44:5-9. 9.
34. Lee J.M., Li J., Johnson D.A., et al. Nrf2, a multi-organ protector. FASEB J 2005, 19:1061-1066.
35. Singh A., Misra V., Thimmulappa R.K., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006, 3:e420.
36. Ohta T., Iijima K., Miyamoto M., et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008, 68:1303-1309.
37. Homma S., Ishii Y., Morishima Y., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009, 15:3423-3432.
38. Padmanabhan B., Tong K.I., Ohta T., et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006, 21:689-700.
39. Muscarella L.A., Parrella P., D'Alessandro V., et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011, 6:710-719.
40. Sjöblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
41. Nioi P., Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 2007, 362:816-821.
42. Shibata T., Kokubu A., Gotoh M., et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008, 135:1358-1368. e1354.
43. Konstantinopoulos P.A., Spentzos D., Fountzilas E., et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011, 71:5081-5089.
44. Hanada N., Takahata T., Zhou Q., et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012, 12:66.
45. Kim Y.R., Oh J.E., Kim M.S., et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010, 220:446-451.
46. Shibata T., Saito S., Kokubu A., Suzuki T., Yamamoto M., Hirohashi S. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res 2010, 70:9095-9105.
47. Lautier D., Luscher P., Tyrrell R.M. Endogenous glutathione levels modulate both constitutive and UVA radiation/hydrogen peroxide inducible expression of the human heme oxygenase gene. Carcinogenesis 1992, 13:227-232.
48. Ossola J.O., Tomaro M.L. Heme oxygenase induction by UVA radiation A response to oxidative stress in rat liver. Int J Biochem Cell Biol 1998, 30:285-292.
49. Tanaka S., Akaike T., Fang J., et al. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br J Cancer 2003, 88:902-909.
50. Motterlini R., Foresti R., Bassi R., Calabrese V., Clark J.E., Green C.J. Endothelial heme oxygenase-1 induction by hypoxia. J Biol Chem 2000, 275:13613-13620.
51. Carraway M.S., Ghio A.J., Carter J.D., Piantadosi C.A. Expression of heme oxygenase-1 in the lung in chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000, 278:L806-L812.
52. Alam J., Stewart D., Touchard C., Boinapally S., Choi A.M., Cook J.L. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999, 274:26071-26078.
53. Goodman A.I., Choudhury M., da Silva J.L., Schwartzman M.L., Abraham N.G. Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 1997, 214:54-75.
54. Becker J.C., Fukui H., Imai Y., et al. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol 2007, 42:852-858.
55. Berberat P.O., Dambrauskas Z., Gulbinas A., et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 2005, 11:3790-3798.
56. Yin Y., Liu Q., Wang B., Chen G., Xu L., Zhou H. Expression of heme oxygenase-1 in human gastric cancer. Exp Biol Med (Maywood) 2012, 237:362-371.
57. Miyake M., Fujimoto K., Anai S., et al. Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer. Urol Int 2010, 85:355-363.
58. Degese M.S., Mendizabal J.E., Gandini N.A., et al. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer 2012, 77:168-175.
59. Kim H.R., Kim S., Kim E.J., et al. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 2008, 60:47-56.
60. Lister A., Nedjadi T., Kitteringham N.R., et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 2011, 10:37.
61. Ewing P., Wilke A., Eissner G., Holler E., Andreesen R., Gerbitz A. Expression of heme oxygenase-1 protects endothelial cells from irradiation-induced apoptosis. Endothelium 2005, 12:113-119.
62. Yokoyama S., Mita S., Okabe A., Abe M., Ogawa M. Prediction of radiosensitivity in human esophageal squamous cell carcinomas with heme oxygenase-1: a clinicopathological and immunohistochemical study. Oncol Rep 2001, 8:355-358.
63. Shibata T., Kokubu A., Saito S., et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011, 13:864-873.
64. Numata I., Okuyama R., Memezawa A., Ito Y., Takeda K., Furuyama K. et alFunctional expression of heme oxygenase-1 in human differentiated epidermis and its regulation by cytokines. J Invest Dermatol 2009, 129:2594-2603.
65. Piao M.S., Park J.J., Choi J.Y., et al. Nrf2-dependent and Nrf2-independent induction of phase 2 detoxifying and antioxidant enzymes during keratinocyte differentiation. Arch Dermatol Res 2012, 304:387-395.
66. Dhakshinamoorthy S., Long D.J., Jaiswal A.K. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cell Regul 2001, 36:201-216.
67. Dinkova-Kostova A.T., Talalay P. Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic Biol Med 2000, 29:231-240.
68. Kato K., Takahashi K., Monzen S., et al. Relationship between radiosensitivity and Nrf2 target gene expression in human hematopoietic stem cells. Radiat Res 2010, 174:177-184.
69. Rhee S.G., Kang S.W., Chang T.S., Jeong W., Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 2008, 52:35-41.
70. Kim Y.J., Ahn J.Y., Liang P., Ip C., Zhang Y., Park Y.M. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res 2007, 67:546-554.
71. Chen M.F., Keng P.C., Shau H., et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 2006, 64:581-591.
72. Guo Q., Huang X., Zhang J., Luo Y., Peng Z., Li S. Downregulation of peroxiredoxin I by a novel fully human phage display recombinant antibody induces apoptosis and enhances radiation sensitization in A549 lung carcinoma cells. Cancer Biother Radiopharm 2012, 27:307-316.
73. Zhang B., Wang Y., Liu K., et al. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem Pharmacol 2008, 75:660-667.
74. You A., Nam C.W., Wakabayashi N., Yamamoto M., Kensler T.W., Kwak M.K. Transcription factor Nrf2 maintains the basal expression of Mdm2: an implication of the regulation of p53 signaling by Nrf2. Arch Biochem Biophys 2011, 507:356-364.
75. Schilling D., Düwel M., Molls M., Multhoff G. Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels. Cell Stress Chaperones 2013, 18:183-191.
76. Wu C.T., Chen W.C., Liao S.K., Hsu C.L., Lee K.D., Chen M.F. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 2007, 14:633-643.
77. Zhao Y., Seefeldt T., Chen W., et al. Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiation. Free Radic Biol Med 2009, 47:176-183.
78. North S., Moenner M., Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005, 218:1-14.
79. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000, 35:71-103.
80. Guzy R.D., Hoyos B., Robin E., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005, 1:401-408.
81. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-648.
82. Harada H. How can we overcome tumor hypoxia in radiation therapy. J Radiat Res 2011, 52:545-556.
83. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
84. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
85. Huang L.E., Arany Z., Livingston D.M., Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996, 271:32253-32259.
86. Bachtiary B., Schindl M., Pötter R., et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003, 9:2234-2240.
87. Hsieh C.H., Lee C.H., Liang J.A., Yu C.Y., Shyu W.C. Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncol Rep 2010, 24:1629-1636.
88. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
89. Zhou S., Ye W., Zhang M., Liang J. The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action. Crit Rev Eukaryot Gene Expr 2012, 22:149-160.
90. Kim T.H., Hur E.G., Kang S.J., et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res 2011, 71:2260-2275.
91. Li F., Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010, 1805:167-180.
92. Chen X., Shen B., Xia L., et al. Activation of nuclear factor κB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 2002, 62:1213-1221.
93. Ahmed K.M., Dong S., Fan M., Li J.J. Nuclear factor-κB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res 2006, 4:945-955.
94. Ahmed K.M., Cao N., Li J.J. HER-2 and NF-κB as the targets for therapy-resistant breast cancer. Anticancer Res 2006, 26:4235-4243.
95. Veuger S.J., Hunter J.E., Durkacz B.W. Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance. Oncogene 2008, 28:832-842.
96. Cao N., Li S., Wang Z., et al. NF-κB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 2009, 171:9-21.
97. Mendonca M.S., Chin-Sinex H., Gomez-Millan J., et al. Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-κB and split-dose repair. Radiat Res 2007, 168:689-697.
98. Tamatani T., Azuma M., Motegi K., Takamaru N., Kawashima Y., Bando T. Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells. Int J Oncol 2007, 31:761-768.
99. Zand H., Rahimipour A., Salimi S., Shafiee S.M. Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-γ activation and NF-κB suppression. Mol Cell Biochem 2008, 317:113-120.
100. Tsuboi Y., Kurimoto M., Nagai S., et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J Neurosurg 2009, 110:594-604.
101. Wang L., Fu J.N., Wang J.Y., et al. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy. Anticancer Drugs 2011, 22:732-740.
102. Multhoff G., Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol 2012, 2:58.
103. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-[kappa] B as the matchmaker. Nat Immunol 2011, 12:715-723.
104. Nair S., Doh S.T., Chan J.Y., Kong A.N., Cai L. Regulatory potential for concerted modulation of Nrf2-and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer 2008, 99:2070-2082.
105. Missero C., Di Cunto F., Kiyokawa H., Koff A., Dotto G.P. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 1996, 10:3065-3075.
106. Mukherjee G., Freeman A., Moore R., et al. Biologic factors and response to radiotherapy in carcinoma of the cervix. Int J Gynecol Cancer 2001, 11:187-193.
107. Lee J.C., Kim H., Lee S.W., et al. The clinical characteristics and expression of P21 in recurrent early glottic cancer after radiation therapy. Korean J Otolaryngol-Head Neck Surg 2005, 48:630-635.
108. Fischer C.A., Jung M., Zlobec I., et al. Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis. Head Neck 2011, 33:267-273.
109. Kokunai T., Tamaki N. Relationship between expression of p21WAF1/CIP1 and radio resistance in human gliomas. Cancer Sci 1999, 90:638-646.
110. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment. Trends Cell Biol 2003, 13:65-70.
111. Zhao W., Robbins M.E.C. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 2009, 16:130-143.
112. O'Reilly M.A., Staversky R.J., Watkins R.H., et al. The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress. Am J Respir Cell Mol Biol 2001, 24:703.
113. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-649.
114. Chen W., Sun Z., Wang X.J., et al. Direct interaction between Nrf2 and p21 Cip1/WAF1 upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009, 34:663-673.
115. Allen D.M., van Praag H., Ray J., et al. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev 2001, 15:554-566.
116. Tribius S., Pidel A., Casper D. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 2001, 50:511-523.
117. Westphal C.H., Hoyes K.P., Canman C.E., et al. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res 1998, 58:5637-5639.
118. Ahmed K.M., Li J.J. ATM-NF-kB connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 2007, 7:335-342.
119. Li B., Wang X., Rasheed N., et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C δ. Genes Dev 2004, 18:1824-1837.
120. Blum R., Gupta R., Burger P.E., et al. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS ONE 2009, 4:e5722.
121. Morel A.P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
122. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
123. Ogasawara M.A., Zhang H. Redox regulation and its emerging roles in stem cells and stem-like cancer cells. Antioxid Redox Signal 2009, 11:1107-1122.
124. Naka K., Muraguchi T., Hoshii T., Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 2008, 10:1883-1894.
125. Kobayashi C.I., Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol 2012, 227:421-430.
126. Phillips T.M., McBride W.H., Pajonk F. The response of CD24-/lowCD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
127. Yang H., Magilnick N., Lee C., et al. Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Mol Cell Biol 2005, 25:5933-5946.
128. Khan N.M., Sandur S.K., Checker R., Sharma D., Poduval T.B., Sainis K.B. Pro-oxidants ameliorate radiation-induced apoptosis through activation of the calcium-ERK1/2-Nrf2 pathway. Free Radic Biol Med 2011, 51:115-128.
129. McDonald J.T., Kim K., Norris A.J., et al. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res 2010, 70:8886-8895.
130. Singh A., Bodas M., Wakabayashi N., Bunz F., Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010, 13:1627-1637.
131. Sharma P.K., Varshney R. 2-Deoxy-d-glucose and 6-aminonicotinamide-mediated Nrf2 down regulation leads to radiosensitization of malignant cells via abrogation of GSH mediated defense. Free Radic Res 2012, 46:1446-1457.
132. Tang X., Wang H., Fan L., et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 2011, 50:1599-1609.
133. Zhong Y., Zhang F., Sun Z., et al. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol Carcinog 2013, 52:824-834.
134. Ren D., Villeneuve N.F., Jiang T., et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 2011, 108:1433-1438.
135. Salazar M., Rojo A.I., Velasco D., de Sagarra R.M., Cuadrado A. Glycogen synthase kinase-3β inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 2006, 281:14841-14851.
136. Kim W.D., Kim Y.W., Cho I.J., Lee C.H., Kim S.G. E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J Cell Sci 2012, 125:1284-1295.
137. Li W., Liu H., Zhou J.S., et al. Caveolin-1 inhibits expression of antioxidant enzymes through direct interaction with nuclear erythroid 2 p45-related factor-2 (Nrf2). J Biol Chem 2012, 287:20922-20930.
138. Loignon M., Miao W., Hu L., et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther 2009, 8:2432-2440.